Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7291 to 7305 of 7710 results

  1. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

    Interventional procedures guidance
    Discontinued

  2. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  3. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Lung transplantation with ex-vivo perfusion

    Discontinued [GID-IP1046]

    Interventional procedures guidance
    Discontinued

  6. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued [GID-MT557]

    Medical technologies guidance
    Discontinued

  7. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued [GID-MT563]

    Medical technologies guidance
    Discontinued

  8. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  9. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Technology appraisal guidance
    Published
    12 May 2021

  13. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development [GID-TA11475] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development [GID-TA11301] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065

    In development [GID-TA11588] Expected publication date: TBC

    Technology appraisal guidance
    In development